Stockholm:PROGEN Prostatype Genomics AB Aktie

What changed lately

• Latest news release · Sep 17, 2026

  Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6

Latest news

All Prostatype Genomics AB news

Financings

• New shares through exercise of warrants of series TO6

  Sep 17, 2026 · US$1.27M

  Closed: SEK 12.5M raised · SEK 0.1 a share · Vator Securities AB +2

  Dealers: Vator Securities AB, Navia Corporate Finance AB, Birchtree Advisory AB

  Buyers: Vator Securities AB (8,156,289 shares at SEK 0.10 in the Directed Share Issue (underwriting and compensation shares))

  Insiders: Letters of intent from the Board of Directors, management and other warrant holders corresponding to approximately SEK 2.27 million

  Use of proceeds: Liquidity and financial position of the company

  Announced Aug 31, 2026 · Closed Sep 17, 2026

• Rights offering of units (shares and warrants of series TO6 and TO7)

  Aug 3, 2026 · US$4.88M

  Closed: SEK 47.4M raised · SEK 0.1 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2

  Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB

  Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, totalling approximately SEK 9.2 million

  Use of proceeds: Accelerate commercialization of Prostatype, strengthen presence in prioritized markets and continue company development

  Update Jul 8, 2026 · Update Jul 9, 2026 · Update Jul 21, 2026 · Closed Jul 27, 2026 · Update Aug 3, 2026

Read by 6ix AI from the company's releases

Prostatype Genomics AB on 6ix

Sector

Health care

Industry

Diagnostics & research services

News releases

15 in the last 12 months · 21 in all · newest Sep 17, 2026 · oldest 2025

Where Prostatype Genomics AB is listed

Log in to ask 6ix AI your own questions about Prostatype Genomics AB.